|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/551 | |
| C07D 495/14 | |||
| A61P 35/00 |
| (11) | Number of the document | 3066101 |
| (13) | Kind of document | T |
| (96) | European patent application number | 14860080.2 |
| Date of filing the European patent application | 2014-11-07 | |
| (97) | Date of publication of the European application | 2016-09-14 |
| (45) | Date of publication and mention of the grant of the patent | 2020-07-29 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2014/064549 |
| Date | 2014-11-07 |
| (87) | Number | WO 2015/070020 |
| Date | 2015-05-14 |
| (30) | Number | Date | Country code |
| 201361901908 P | 2013-11-08 | US |
| (72) |
BRADNER, James, E., US
MCKEOWN, Michael, R., US
SHIPP, Margaret, A., US
CHAPUY, Bjoern, US
WONG, Kwok, Kin, US
CHEN, Zhao, US
|
| (73) |
Dana-Farber Cancer Institute, Inc.,
450 Brookline Avenue, Boston, MA 02215,
US
|
| (54) | COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS |
| COMBINATION THERAPY FOR CANCER USING BROMODOMAIN AND EXTRA-TERMINAL (BET) PROTEIN INHIBITORS |